Antibody-Drug Conjugates in Uro-Oncology.
Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment. An...
| Publicado en: | Targeted Oncology Vol. 17; no. 3; pp. 203 - 222 |
|---|---|
| Autores principales: | , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
May2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157586542&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 157586542 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: May2022 vid: 17 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 157586542 157586542 NLM35567672 157586542 10.1007/s11523-022-00872-3 NLM35567672 157586542 ppf: 203 ppct: 19 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Antibody-Drug Conjugates in Uro-Oncology. aug: au: Sigorski, Dawid Różanowski, Paweł Iżycka-Świeszewska, Ewa Wiktorska, Katarzyna affil: Department of Oncology, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland sug: subj: Carcinoma, Transitional Cell Drug Therapy Antineoplastic Agents Pharmacodynamics Antibodies Pharmacodynamics Antineoplastic Agents Therapeutic Use Antibodies Therapeutic Use Human Male Scales Male ab: Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment. Antibody-drug conjugates (ADCs) are a relatively new concept in cancer treatment that broaden therapeutic landscape. ADCs are examples of a 'drug delivery into the tumor' system composed of an antigen-directed antibody linked to a cytotoxic drug that may release cytotoxic components after binding to the antigen located on the surface of tumor cells. The clinical properties of drugs are influenced by every component of ADCs. Regarding uro-oncology, enfortumab vedotin (EV) and sacituzumab govitecan (SG) are currently registered for patients with locally advanced or metastatic urothelial cancer following previous treatment with an immune checkpoint inhibitor (iCPI; programmed death receptor-1 [PD-1] or programmed death-ligand 1 [PD-L1]) inhibitor) and platinum-containing chemotherapy. The EV-301 trial showed that EV significantly prolonged the overall survival compared with classic chemotherapy. The TROPHY-U-01 trial conducted to evaluate SG demonstrated promising results as regards the objective response rate and duration of response. The safety and efficacy of ADCs in monotherapy and polytherapy (mainly with iCPIs) for different cancer stages and tumor types are assessed in numerous ongoing clinical trials. The aim of this review is to present new molecular biomarkers, specific mechanisms of action, and ongoing clinical trials of ADCs in genitourinary cancers. In the expert discussion, we assess the place of ADCs in uro-oncology and discuss their clinical value. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|